VR Logo

Cyclerion Therapeutics Inc. (CYCN) download report


Healthcare | Biotechnology & Pharma Research

Cyclerion Therapeutics Inc. (CYCN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.

IPO Date: 02-Apr-2019

CEO & Director: Dr. Peter M. Hecht Ph.D.

Chief Operating Officer: Ms. Cheryl Gault

Listing: NASDAQ: CYCN

Country: United States

Headquarters: Cambridge, MA

Website: https://www.cyclerion.com

Key Facts

Market cap: $25.20 Mln

Revenue (TTM): $4.11 Mln

Earnings (TTM): $-51.23 Mln

Cash: $41.13 Mln

Total Debt: $0.00 Mln

Insider's Holding: 13.55%

Liquidity: Low

52 Week range: $0.46 - 4.23

Shares outstanding: 43,448,400

6 Years Aggregate:

  • CFO: $-439.82 Mln
  • EBITDA: $-452.87 Mln
  • Net Profit: $-525.19 Mln

Stock Performance

Time Period Cyclerion Therapeutics (CYCN) S&P BSE Sensex S&P Small-Cap 600
YTD-66.28-9.18-18.78
1 month-2.52-4.78-8.00
3 months-47.75-9.66-13.65
1 Year-85.130.81-17.19
3 Years-63.0010.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Cyclerion Therapeutics (CYCN) S&P Small-Cap 600 S&P BSE Sensex
2021-43.7925.2721.99
202012.509.5715.75